The company will use the facility to run clinical pharmacology studies in healthy, diabetic and obese participants. The facility is also adjacent to one of the largest endocrinology practices in the country.

Cetero has access to patients who are Type I and Type II diabetics, patients with hypogonadism, neuropathy, osteoporosis and erectile dysfunction. As a result, pharmaceutical companies can contract with Cetero to test the efficacy of new drugs in a clinical setting with a goal for advancing treatment options for patients.

The new facility consolidates Cetero’s operations in one four-story building.

“Our staff is very excited about working under one roof in the new facility. The building was designed to house healthy and patient populations participating in first-in-human and proof-of-concept studies, as well as very complex euglycemic and insulin-clamp studies,” says Dr. Robert Earl, president of Cetero’s San Antonio facility. “San Antonio’s highly-respected principal investigators, nurses and study managers have many years of experience running Phase I to Phase IV studies for biotechnology, device and pharmaceutical companies.”

Cetero Research has conducted clinical studies for more than 25 years. The company has a total of six clinical pharmacology facilities that provide early clinical development services.

www.cetero.com

Industries:

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.